Metabolomics in cancer research and emerging applications in clinical oncology

DR Schmidt, R Patel, DG Kirsch… - CA: a cancer journal …, 2021 - Wiley Online Library
Cancer has myriad effects on metabolism that include both rewiring of intracellular
metabolism to enable cancer cells to proliferate inappropriately and adapt to the tumor …

Indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

K Tang, YH Wu, Y Song, B Yu - Journal of Hematology & Oncology, 2021 - Springer
Abstract Indoleamine 2, 3-dioxygenase 1 (IDO1) is a heme enzyme that catalyzes the
oxidation of L-tryptophan. Functionally, IDO1 has played a pivotal role in cancer immune …

Molecular mechanisms of treatment resistance in glioblastoma

A Ou, WKA Yung, N Majd - International journal of molecular sciences, 2020 - mdpi.com
Glioblastoma is the most common malignant primary brain tumor in adults and is almost
invariably fatal. Despite our growing understanding of the various mechanisms underlying …

Immune microenvironment in glioblastoma subtypes

Z Chen, D Hambardzumyan - Frontiers in immunology, 2018 - frontiersin.org
Glioblastomas (GBMs) are the most common and aggressive primary brain tumors. Due to
their malignant growth and invasion into the brain parenchyma coupled with resistance to …

IDO1 in cancer: a Gemini of immune checkpoints

L Zhai, E Ladomersky, A Lenzen, B Nguyen… - Cellular & molecular …, 2018 - nature.com
Abstract Indoleamine 2, 3-dioxygenase 1 (IDO1) is a rate-limiting metabolic enzyme that
converts the essential amino acid tryptophan (Trp) into downstream catabolites known as …

Current immunotherapies for glioblastoma multiforme

B Huang, X Li, Y Li, J Zhang, Z Zong… - Frontiers in …, 2021 - frontiersin.org
Glioblastoma multiforme (GBM) is the most common and aggressive malignant tumor found
in the central nervous system. Currently, standard treatments in the clinic include maximal …

The role of indoleamine-2, 3-dioxygenase in cancer development, diagnostics, and therapy

L Hornyák, N Dobos, G Koncz, Z Karányi… - Frontiers in …, 2018 - frontiersin.org
Tumors are composed of abnormally transformed cell types and tissues that differ from
normal tissues in their genetic and epigenetic makeup, metabolism, and immunology …

Immunosuppressive IDO in cancer: mechanisms of action, animal models, and targeting strategies

L Zhai, A Bell, E Ladomersky, KL Lauing… - Frontiers in …, 2020 - frontiersin.org
Indoleamine 2, 3-dioxygenase 1 (IDO; IDO1; INDO) is a rate-limiting enzyme that
metabolizes the essential amino acid, tryptophan, into downstream kynurenines …

Tumor heterogeneity in glioblastomas: from light microscopy to molecular pathology

AP Becker, BE Sells, SJ Haque, A Chakravarti - Cancers, 2021 - mdpi.com
Simple Summary Glioblastomas (GBMs) are the most frequent and aggressive malignant
tumors arising in the human brain. One of the main reasons for GBM aggressiveness is its …

Mouse models of glioblastoma for the evaluation of novel therapeutic strategies

AF Haddad, JS Young, D Amara… - Neuro-oncology …, 2021 - academic.oup.com
Glioblastoma (GBM) is an incurable brain tumor with a median survival of approximately 15
months despite an aggressive standard of care that includes surgery, chemotherapy, and …